Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed First North Stockholm
10/15/2020 10/16/2020 10/19/2020 10/20/2020 10/21/2020 Date
37.3(c) 37.2(c) 37(c) 36.4(c) 35.1 Last
46 890 21 985 39 078 64 607 92 725 Volume
-4.36% -0.27% -0.54% -1.62% -3.57% Change
More quotes
Financials
Sales 2021 19,5 M 2,24 M 2,24 M
Net income 2021 -32,5 M -3,73 M -3,73 M
Net cash position 2021 6,50 M 0,75 M 0,75 M
P/E ratio 2021 -25,3x
Yield 2021 -
Sales 2022 45,5 M 5,22 M 5,22 M
Net income 2022 -17,0 M -1,95 M -1,95 M
Net Debt 2022 18,0 M 2,07 M 2,07 M
P/E ratio 2022 -48,1x
Yield 2022 -
Capitalization 992 M 114 M 114 M
EV / Sales 2021 50,6x
EV / Sales 2022 22,2x
Nbr of Employees 21
Free-Float 70,3%
More Financials
Company
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates... 
More about the company
Notations Surperformance© of Biovica International AB (publ)
Trading Rating : Investor Rating :
More Ratings
All news about BIOVICA INTERNATIONAL AB (PUBL)
09/25BIOVICA INTERNATIONAL : completes 510(k) submission for DiviTum®TKa to the FDA
AQ
08/27BIOVICA INTERNATIONAL : Bulletin from the annual general meeting in Biovica
AQ
08/27BIOVICA Q1 INTERIM REPORT : May-July 2020/2021
AQ
08/26BIOVICA INTERNATIONAL : carries out a directed share issue of Class B shares and..
AQ
08/26BIOVICA INTERNATIONAL : intends to carry out a directed share issue of Class B s..
AQ
08/26BIOVICA INTERNATIONAL : successfully completes clinical validation for DiviTum® ..
AQ
07/22BIOVICA INTERNATIONAL PUBL : Notice to AGM for Biovica International AB
AQ
06/30BIOVICA INTERNATIONAL AB : – Annual Report for the fiscal year 2019/2020 p..
AQ
06/17BIOVICA INTERNATIONAL PUBL : completes analytical validation as part of FDA appl..
AQ
06/05Biovica Year-end Report for 2019/2020
AQ
05/22BIOVICA INTERNATIONAL PUBL : DiviTum® acknowledged in ASCO educational book
AQ
05/11BIOVICA INTERNATIONAL PUBL : DiviTum® and TK activity acknowledged in highly ren..
AQ
05/11BIOVICA INTERNATIONAL PUBL : provides market share target at today's Capital Mar..
AQ
05/06REMINDER : Biovica invites to virtual Capital Markets Day 11 May
AQ
05/06REMINDER : Biovica invites to virtual Capital Markets Day 11 May
AQ
More news
News in other languages on BIOVICA INTERNATIONAL AB (PUBL)

- No features available -

More news
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price 31,00 SEK
Last Close Price 35,10 SEK
Spread / Highest target -11,7%
Spread / Average Target -11,7%
Spread / Lowest Target -11,7%
EPS Revisions
Managers
NameTitle
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist Director-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOVICA INTERNATIONAL AB (PUBL)208.47%118
EXACT SCIENCES CORPORATION15.85%15 470
GUARDANT HEALTH, INC.30.43%10 153
BGI GENOMICS CO., LTD.106.55%8 593
ADAPTIVE BIOTECHNOLOGIES CORPORATION61.20%6 549
SEEGENE INC--.--%6 228